Cover Image
市場調查報告書

Anacor Pharmaceuticals, Inc.:開發中產品分析

Anacor Pharmaceuticals, Inc. - Product Pipeline Review - 2016

出版商 Global Markets Direct 商品編碼 203702
出版日期 內容資訊 英文 49 Pages
訂單完成後即時交付
價格
Back to Top
Anacor Pharmaceuticals, Inc.:開發中產品分析 Anacor Pharmaceuticals, Inc. - Product Pipeline Review - 2016
出版日期: 2016年04月27日 內容資訊: 英文 49 Pages
簡介

Anacor Pharmaceuticals, Inc正在從事利用硼化學平台所得之治療傳染症、炎症用小分子治療藥之開發及上市。Anacor的主要開發中產品有灰指甲治療藥之tavaborole(局部抗真菌藥物),及異位性皮膚炎·乾癬治療藥之AN2728(局部抗發炎藥)等。此外該公司在臨床實驗中的候補藥包含了AN2718和AN2898(tavaborole和AN2728後備化合物),革蘭氏陰性菌原因的感染疾病治療藥AN3365(抗生素)等。

本報告提供美國的生物醫藥品企業,Anacor Pharmaceuticals, Inc.(Anacor)的醫藥品的研究開發的進展相關分析,開發平台的整體結構,臨床實驗的整體進展,彙整主要開發中產品簡介與開發情形,該公司簡介等訊。

目錄

Anacor Pharmaceuticals, Inc.:現狀

  • 企業概要
  • 主要資訊
  • 主要資料

研究開發(R&D)概況

  • 主要的治療領域

開發平台·檢討

  • 各開發階段的開發中產品
  • 開發中產品:單劑治療藥
  • 開發中產品:轉出授權產品
    • 轉出授權產品/並用治療模式

開發中產品的概要

  • 最後階段的開發中產品
    • 第Ⅲ相的產品/聯合治療模式
  • 臨床實驗階段的開發中產品
    • 第二階段產品/並用治療模式
    • 第一階段產品/並用治療模式
  • 初期階段的開發中產品
    • 臨床實驗前產品/並用治療模式
    • 藥物研發階段的產品/並用治療模式

藥物簡介

  • crisaborole
    • 產品概要
    • 作用機制
    • 研究開發(R&D)的發展
  • AN-2898
  • AN-3365
  • AN-2718
  • AN-3485
  • AN-4161
  • AN-4169
  • AN-5973
  • Small Molecule 1 for Tuberculosis
  • Small Molecule 2 for Tuberculosis
  • Small Molecule for Shigellosis
  • Small Molecules for Chagas Disease
  • Small Molecules for Leishmaniasis
  • Small Molecules for Nematodal Diseases
  • Small Molecules to Inhibit PDE4 for Psoriasis

開發平台分析

  • 標的別
  • 各投藥法
  • 各分子類型
  • 各作用機制

開發中產品的最新趨勢

開發暫停的產品

開發中止的產品

  • 開發中止的產品簡介
    • AN-3365

公司所在地及子公司

  • 總公司

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC08033CDB

Summary

Global Markets Direct's, 'Anacor Pharmaceuticals, Inc. - Product Pipeline Review - 2016', provides an overview of the Anacor Pharmaceuticals, Inc.'s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Anacor Pharmaceuticals, Inc., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the pipeline therapeutic landscape of Anacor Pharmaceuticals, Inc.
  • The report provides overview of Anacor Pharmaceuticals, Inc. including its business description, key facts, and locations and subsidiaries
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report assesses Anacor Pharmaceuticals, Inc.'s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report features Anacor Pharmaceuticals, Inc.'s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

  • Evaluate Anacor Pharmaceuticals, Inc.'s strategic position with total access to detailed information on its product pipeline
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Anacor Pharmaceuticals, Inc.
  • Identify potential new clients or partners in the target demographic
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Anacor Pharmaceuticals, Inc.'s pipeline depth and focus of pipeline therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Anacor Pharmaceuticals, Inc. Snapshot
    • Anacor Pharmaceuticals, Inc. Overview
    • Key Information
    • Key Facts
  • Anacor Pharmaceuticals, Inc. - Research and Development Overview
    • Key Therapeutic Areas
  • Anacor Pharmaceuticals, Inc. - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Out-Licensed Products
      • Out-Licensed Products/Combination Treatment Modalities
  • Anacor Pharmaceuticals, Inc. - Pipeline Products Glance
    • Anacor Pharmaceuticals, Inc. - Late Stage Pipeline Products
      • Pre-Registration Products/Combination Treatment Modalities
    • Anacor Pharmaceuticals, Inc. - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
      • Phase I Products/Combination Treatment Modalities
    • Anacor Pharmaceuticals, Inc. - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
      • Discovery Products/Combination Treatment Modalities
  • Anacor Pharmaceuticals, Inc. - Drug Profiles
    • crisaborole
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • epetraborole
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • AN-2718
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • AN-3485
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • AN-4161
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • AN-4169
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • AN-5973
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule 1 for Tuberculosis
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule 2 for Tuberculosis
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule for Shigellosis
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules for Chagas Disease
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules for Leishmaniasis
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules for Nematodal Diseases
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules for Skin Inflammation
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules to Inhibit PDE4 for Psoriasis
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Anacor Pharmaceuticals, Inc. - Pipeline Analysis
  • Anacor Pharmaceuticals, Inc. - Pipeline Products by Target
  • Anacor Pharmaceuticals, Inc. - Pipeline Products by Route of Administration
  • Anacor Pharmaceuticals, Inc. - Pipeline Products by Molecule Type
  • Anacor Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action
  • Anacor Pharmaceuticals, Inc. - Recent Pipeline Updates
  • Anacor Pharmaceuticals, Inc. - Dormant Projects
  • Anacor Pharmaceuticals, Inc. - Discontinued Pipeline Products
    • Discontinued Pipeline Product Profiles
      • epetraborole
  • Anacor Pharmaceuticals, Inc. - Locations And Subsidiaries
    • Head Office
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Anacor Pharmaceuticals, Inc., Key Information
  • Anacor Pharmaceuticals, Inc., Key Facts
  • Anacor Pharmaceuticals, Inc. - Pipeline by Indication, 2016
  • Anacor Pharmaceuticals, Inc. - Pipeline by Stage of Development, 2016
  • Anacor Pharmaceuticals, Inc. - Monotherapy Products in Pipeline, 2016
  • Anacor Pharmaceuticals, Inc. - Out-Licensed Products in Pipeline, 2016
  • Anacor Pharmaceuticals, Inc. - Out-Licensed Products/ Combination Treatment Modalities, 2016
  • Anacor Pharmaceuticals, Inc. - Pre-Registration, 2016
  • Anacor Pharmaceuticals, Inc. - Phase II, 2016
  • Anacor Pharmaceuticals, Inc. - Phase I, 2016
  • Anacor Pharmaceuticals, Inc. - Preclinical, 2016
  • Anacor Pharmaceuticals, Inc. - Discovery, 2016
  • Anacor Pharmaceuticals, Inc. - Pipeline by Target, 2016
  • Anacor Pharmaceuticals, Inc. - Pipeline by Route of Administration, 2016
  • Anacor Pharmaceuticals, Inc. - Pipeline by Molecule Type, 2016
  • Anacor Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action, 2016
  • Anacor Pharmaceuticals, Inc. - Recent Pipeline Updates, 2016
  • Anacor Pharmaceuticals, Inc. - Dormant Developmental Projects,2016
  • Anacor Pharmaceuticals, Inc. - Discontinued Pipeline Products, 2016

List of Figures

  • Anacor Pharmaceuticals, Inc. - Pipeline by Top 10 Indication, 2016
  • Anacor Pharmaceuticals, Inc. - Pipeline by Stage of Development, 2016
  • Anacor Pharmaceuticals, Inc. - Monotherapy Products in Pipeline, 2016
  • Anacor Pharmaceuticals, Inc. - Out-Licensed Products in Pipeline, 2016
  • Anacor Pharmaceuticals, Inc. - Pipeline by Target, 2016
  • Anacor Pharmaceuticals, Inc. - Pipeline by Route of Administration, 2016
  • Anacor Pharmaceuticals, Inc. - Pipeline by Molecule Type, 2016
  • Anacor Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action, 2016
Back to Top